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ADDENDUM II 
Valorization 
Relevance 
The overall aim of this thesis was to investigate what regulatory roles microRNAs and 
epigenetic changes (i.e. DNA methylation) have in transcriptomic responses induced by 
genotoxic and non-genotoxic carcinogens in cell models relevant for liver carcinogenicity. 
Furthermore, the application of the expression patterns of these regulatory molecules (i.e. 
microRNAs and DNA methylation changes), for the purpose of discriminating between 
different classes of chemical compounds (i.e. genotoxic carcinogens (GTXC), non-genotoxic 
carcinogens (NGTXC) and non-carcinogens (NC)), was evaluated in the context of 
genotoxicity and carcinogenicity testing. Cancer is the number one cause of death worldwide1. 
According to the World Health Organization, liver cancer, specifically hepatocellular 
carcinoma (HCC) is the sixth most prevalent and the second most lethal type of cancer 
worldwide2. Exposure to hazardous agents (e.g. chemicals, food-additives or pharmaceuticals) 
appears to be of major influence in the induction of human cancers. For this reason, it is 
extremely important that the carcinogenic potential of new agents is accurately predicted. 
Traditionally, carcinogens are divided based on their mode of action (MOA) into DNA-
reactive genotoxic (GTX) carcinogens and non DNA-reactive or non-genotoxic (NGTX) 
carcinogens3. Avoidance of exposure to such carcinogens may prevent 30% of all HCC cases4. 
The safe use of these agents and accurate testing of their toxic effects is of economical as well 
as societal concern.  
Valorization of scientific knowledge is defined as the process of value-creation out of 
knowledge, by making this knowledge suitable and available for economic or societal 
utilization and to translate this into high-potential products, services, processes and industrial 
activity. 
Economic relevance 
Economic utilization of the current obtained scientific knowledge should be focused on 
developing alternative, improved and less expensive in vitro tests which are able to better 
predict the in vivo genotoxic and carcinogenic potential of novel hazardous agents (e.g. 
chemicals, food-additives or pharmaceuticals). Development, application and 
commercialization of improved test methods in human risk assessment by industry leads to 
products which are safer leading to a higher competitive value and are thus more profitable.  
Societal relevance 
Societal utilization of the scientific knowledge originating from this current thesis should be 
dedicated to follow-up research focused on the development of so called adverse outcome 
pathways (AOP) by the global organization, Organization for Economic Co-operation and 
Development (OECD)5. The OECD actually launched a program in 2012 on the development 
of AOPs that should contribute to an improved risk assessment of human carcinogens. The 
definition of an AOP, as meant by the OECD, is an analytical concept that describes a linear 
sequence of causally related key events (KE) within the different molecular layers of the 
biological organization; starting with a so called molecular initiation event (MIE) that ultimately 
lead to an adverse outcome (AO), represented by a health or toxicological effect such as the 
development of HCC. The linkage between the events is described by key event relationships 
(KER). Ideally these AOPs, and information on these related events, should all be collected 
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within an open-source web-based interface, namely the AOP Knowledge Base (AOP KB) 
(https://aopkb.org/). The project focused on collecting this type of information is led by the 
OECD, the U.S. Environmental Protection Agency (EPA) and the European Commission's 
Joint Research Center (JRC). AOPs are the central element of a toxicological knowledge 
framework being built to support chemical risk assessment based on mechanistic reasoning. 
Such AOPs should also be included in the guidance documents developed by an initiative of 
the European Union through the Registration, Evaluation, Authorization and restrictions of 
Chemicals (REACH)6.  
In addition the generation of improved novel alternative in vitro test methods could on the long 
run, replace the use of animals for genotoxicity and carcinogenicity testing, within human risk 
assessment, thereby complying with the societal demand for reducing animal-based testing. 
Target groups 
Industry 
The mechanistic knowledge obtained in this current thesis might be used within future 
translational research aimed at developing in vitro applications that accurately predict the 
carcinogenic potential of a novel agent developed by chemical, food or pharmaceutical 
industry. Especially specific response profiles of genes or other biomarkers may be utilized for 
developing such alternative test systems. This may fulfill the economic demand of creating 
products which are safer to use thereby generating more competitive products.  
Regulatory organizations 
In Europe, specialized organizations such as the European Chemical Association (ECHA)6, 
European Food Safety Authority (EFSA)7 and the European Medicines Agency/U.S. Food 
and Drug Administration (EMA/FDA)8,9 are responsible for the safe use of chemicals, food-
additives and pharmaceuticals, respectively. Regulations and recommendations are provided by 
global initiatives such as the guidelines developed by the OECD5 or by the European Union 
through REACH6.  
New chemicals, food-additives or drugs first need to be extensively tested for their potential 
hazards and risks to human health and the environment, before they enter the public market. 
Human risk assessment is based on toxicological tests performed with short-term in vitro assays 
and (sub-) chronic animal experiments. The animal experiments, mainly using mice and rats, 
are used to estimate the human cancer risks, but are very expensive and time consuming as 
they require many animals and a large amount of test compound during a period of usually 2 
years. The effectiveness, reliability and relevance of these in vivo animal experiments are 
questioned, especially with regards to the extrapolation of data from animal to humans and 
from short-term experiments in animals to long-term real-life exposure in man10. Due to 
inconsistencies within the translation of testing results from rodents to humans, certain 
undetected carcinogenic compounds may enter the market while other compounds are 
incorrectly withdrawn from the market due to their exclusive carcinogenic potential in 
rodents11.  
Withdrawal of a novel agent from the public market may have tremendous financial 
consequences for industry. Therefore, the demand for alternative testing methods, for better 
predicting human cancer risks, is increasing and new high throughput in vitro methods need to 
199 
ADDENDUM II 
be developed. Numerous relatively cheap in vitro tests are available (e.g. bacterial Ames test, 
mouse lymphoma test, micronucleus test and the chromosomal aberration test) to determine if 
a compound or drug has carcinogenic potential, however these are characterized by a high false 
positive rate (falsely predicted to be carcinogenic when compared with in vivo data)12,13. Many 
compounds that are tested positively in vitro therefore need additional animal tests, which thus 
may be unnecessary. Further development of reliable standardized in vitro tests is therefore 
requested by the OECD and REACH as well as industry which correctly predict human cancer 
risks6. The focus of the development of these alternative models may very well be on liver-
based systems. The liver is responsible for the processing of chemical compounds to potential 
carcinogens and is also a major target organ.  In the last decade the development of new 
alternative test systems has focused on the application of novel technologies, thereby enabling 
complete monitoring of the effects of carcinogens in a cell which allows us to better 
understand why these compounds cause cancer in the long run. The field of toxicogenomics, 
in which this so called systems biology approach may be applied, can be extremely helpful in 
improving the translation of the in vitro setting to the in vivo situation14-16.  
Furthermore, toxicogenomics-based alternative in vitro assays may help in a better 
understanding of the regulatory mechanisms (e.g. epigenetic events such as DNA methylation 
or via non-coding microRNAs) underlying the carcinogenic potential of certain types of 
agents. The findings from Chapter 3 might be useful in developing a cross-omics based AOP 
for GTXC versus NGTXC, in which the roles of microRNAs in chemically-induced 
carcinogenesis leading towards HCC may provide an added value. Especially the findings, 
presented in Chapter 5, 6 and 7, regarding the persistent effects on the microRNA and gene 
expression and DNA methylation level after, in this case, termination of AFB1 treatment in 
primary human hepatocytes (PHH) may add a new perspective on AOPs for carcinogenicity in 
particular and toxicity in general. An increased understanding of chemically-induced 
carcinogenesis and especially the persistency of the induced effects due to carcinogen 
treatment, may lead towards an improved risk assessment of chemical carcinogens within 
humans by contributing to a controlled regulatory environment in which the safe use of 
products and processes is guaranteed. This may ultimately lead to an improvement of health of 
patients and consumers.  
The development of AOPs may therefore facilitate in a better prediction of for example the 
onset of HCC 17. In the AOP Knowledge Base wiki 
(https://aopkb.org/aopwiki/index.php/Main_Page) there is currently an AOP under review 
named “AFB1: Mutagenic Mode-of-Action leading to Hepatocellular Carcinoma (HCC)” 
developed by the working group of OECD Project 2.8 focused on developing AOPs for 
Mutagenic Modes of Action for Cancer. Our obtained regulatory networks could provide 
added value to this AOP and may therefore be uploaded to the AOP Knowledge Base wiki 
and reviewed by the OECD. The epigenetic- and microRNA-directed regulatory networks 
obtained within this current study might therefore be used for further development of AOPs 
characteristic for a particular type of exposure but could also be useful in generating AOPs 
representative for more general responses (GTX versus NGTX carcinogen exposure)18.  
Activities or products 
Commercialized in vitro test system 
mRNA expression-based in vivo and in vitro tests have already proven to be successful in 
separating, specifically, human cells or rats treated with GTX from NGTX carcinogens 19-21. 
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The gene expression found within Chapter 4 could therefore be used for the development of 
an alternative in vitro test system which could be detected by a dedicated PCR- or microarray-
based test system within PMH. Such an alternative test system should then be accompanied 
with a standard operating procedure (SOP) concerning: 1) how to effectively culture PMH and 
2) how to design a sophisticated experiment. This concept could then be commercially sold as
a quick and standardized ready-to-go test system for the evaluation of carcinogenic properties
of novel chemical compounds.
Adverse Outcome Pathways (AOP) 
AOPs might be developed representing a set of characteristic responsive molecules and their 
behavior or expression within a cell, in response to a given exposure with a particular 
compound. By defining particular classes of toxicity, using prototypical model compounds, 
chemical AOPs may be established which can be used for a better mechanistic understanding 
and prediction of toxicity of new compounds, food-additives or pharmaceuticals. Generation 
of AOPs representing important events in genotoxicity and carcinogenicity should be included 
in regulatory guidance documents for the testing of novel agents.  Therefore, the obtained 
persistently affected genes (non-methylated/methylated and/or differentially up/down 
regulated) and microRNAs, which were found in this current thesis after termination of AFB1 
treatment in PHH (Chapter 5 – 7), could be form the basis for the development of such an 
AOP. 
Innovation 
Dedicated gene expression platforms 
The main innovative value of the obtained results is to be found in the applicability of a gene 
expression pattern, more specifically the differentially expressed genes, within an 
commercialized test system which may improve the in vitro-based prediction of in vivo 
genotoxicity and carcinogenicity. In Chapter 4 we initially aimed at developing a similar test 
system which was preferably based on microRNA expression profiles; however, we were not 
successful. Instead, we were able to establish such a predictive signature for genotoxicity and, 
specifically, non-genotoxic carcinogenicity which was based on gene expression profiles. Such 
an expression profile based on mRNA data has already been proven successful in predicting in 
vivo genotoxicity with the use of in vitro cultured HepG2 cells by Magkoufopoulou and 
colleagues19. This in vitro-based expression profile has been patented and licensed out to the 
spin off company ToxGenSolutions (http://www.toxgensolutions.eu/) to develop a 
commercialized PCR-based platform. A comparable platform may thus  be developed focused 
on an improved prediction of in vivo genotoxicity or non-genotoxic carcinogenicity. Our robust 
gene expression profile could be applied which is based on in vitro transcriptomics data 
originating from exposed primary mouse hepatocytes. The availability of a more accurate in 
vitro test system may greatly benefit big partners in industry since such a method would lead to 
the production of safer and more competitive products with a higher market value.  
Improvement of mechanistic understanding 
Furthermore, within this thesis we were able to establish the basis for the development of 
AOPs, important within genotoxicity and carcinogenicity related events, using a set of 
prototypical model compounds.  These AOPs could improve the current understanding of 
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how chemicals provoke toxic events leading to a pathological outcome. Therefore the results 
of this thesis improve the current knowledge with regards to mechanism of toxicity.  
Implementation 
The development of an appropriate AOP for chemically-induced carcinogenesis could improve 
the mechanistic understanding of toxicological endpoints related with certain pathologies. 
Replacing animal experiments with an improved and more mechanistically relevant alternative 
test system may generate major societal as well as economic impact. Furthermore, better 
insights into carcinogenic mechanisms might lead to more efficient and cost-effective future 
experiments.  
Economic implementation 
Therefore, in order to further validate the use of potential biomarker genes or microRNAs for 
the development of an alternative in vitro test system, the current results from this thesis need 
to be further expanded with more test chemicals. Also for the development of potential 
biomarkers of genotoxicity or carcinogenicity this is relevant in order to further develop the 
training set of compounds. The training set of compounds is used to establish the chemical 
specific biomarkers. When the training set is sufficiently large and accurate biomarkers are 
established, the tests needs to be reviewed and validated by an independent laboratory with a 
group of test compounds. The data from these extended experiments then need to be used 
within appropriate prediction software programs that are able to accurately predict the toxic 
potential of the tested compound. For achieving economic impact, preferably, the biomarkers 
need to be patented. This may be commercialized by developing a standardized dedicated 
analytical platform as well as software for the analysis of the data.  
Societal implementation 
Furthermore, in order to get the new test generally accepted in chemical safety assessment, 
recognition by regulatory authorities is required. Validation of this new method therefore 
needs to be reviewed by the European Centre for the Validation of Alternative Methods 
(ECVAM)22 in order to evaluate the reproducibility and the robustness of this assay. When the 
new tests finds acceptance by ECVAM it may be implemented as an EU test method and 
included in the EU Test Methods Regulation or as an OECD Test Guideline5. The OECD 
Test Guidelines are a collection of internationally agreed test methods used by government, 
industry and independent laboratories.  They are used to determine the safety of chemicals and 
chemical preparations, including pesticides and industrial chemicals.  
Other ways of valorization by then also include instructing and informing personal from 
governmental institutes, industry and independent laboratories about these new guidelines in 
order to allow correct application of the new test method.  
The results from this thesis may form the preliminary basis for developing such AOP- or 
biomarker-focused alternative tests systems thereby contributing to a more accurate prediction 
of carcinogenicity for human risk assessment.  
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